Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 21

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
.

NOTE 12 – SUBSEQUENT EVENTS

Sales of Common Stock

During the period from April 1, 2025 through May
8, 2025, the Company sold 279,966 shares of its common stock through its ATM program for net proceeds of $2.1 million.

Collaboration Agreement

During April 2025, INmune Bio International Limited,
a wholly-owned subsidiary of the Company and a vendor entered into a collaboration agreement pursuant to which we were granted a two year
lease for manufacturing space in the United Kingdom. The collaboration agreement requires a deposit of approximately $0.5 million, an
upfront payment of approximately $0.2 million and additional minimum payments of approximately $1.3 million in the first year and approximately
$2.6 million in the second year in addition to certain variable payments based on facility usage.

16

Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations

Forward-Looking Statements

This Form 10-Q contains certain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements
contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting
the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,”
“estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. These
statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety
of factors, many of which are not within our control. These factors include but are not limited to economic conditions generally and in
the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors;
technological advances and failure to successfully develop business relationships.

Description of Business

Overview

Our objective is to develop and commercialize our product candidates
to treat diseases where the innate immune system is dysfunctional causing or contributing to the patient’s disease. Innate immune
dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays a significant role
in the development of immune dysfunction. Innate immune dysfunction can be seen in cancer where Natural Killer (“NK”) cells
are impaired and facilitate a tumor’s evasion of the immune system and subsequent disease progression. Chronic inflammation is implicated
in neurologic and metabolic diseases where it imp